



NEW YORK PHARMA FORUM

NOVEMBER 12, 2012

TOPIC: Transitioning from Established Biopharma to Life Science Startup

SPEAKERS: Blaine McKee, Ph.D.

Executive Vice President & Chief Business Officer, 480 Biomedical

Sapan Shah, Ph.D.

President and Chief Executive Officer, ARMGO Pharma Inc.

MODERATOR: John Keller, Ph.D.

President & Chief Executive Officer, Shionogi Inc.

On November 12th we will welcome back two former presidents of New York Pharma Forum, Dr. Blaine McKee and Dr. Sapan Shah, for an unusual program focused on the transition each of them has gone through in moving from much bigger, well-established public companies (Genzyme and Shionogi, respectively) to serving on the top management teams of life science startups. The format will be an informal conversation with the current president and CEO of Shionogi Inc., Dr. John Keller.

Dr. Shah and Dr. McKee will answer questions about the management challenges they face and how they differ from working at Shionogi and Genzyme; what they find exciting about it, what is frustrating; what it's like working with VC backing as opposed to answering to shareholders; as well as about the science their companies are working on and how they fit into the industry, what competing technologies exist and how they differ. There will be plenty of opportunity for audience participation, so come prepared with your own questions.

ARMGO Pharma Inc. is a biopharma company that is developing small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. 480 Biomedical is developing a bioresorbable scaffold or stent for treating occlusive disease in the superficial femoral artery (SFA), which is now undergoing human trials.